Study of Tarceva and Targretin in Stage I-II Lung Cancer

Completed · Not applicable

Conditions studied: Carcinoma, Non-small-cell Lung

In brief

The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Key facts

Study ID

NCT00125372

Run by

Dartmouth-Hitchcock Medical Center

People needed

12

Starts

2005-12-01

Expected to finish

2010-08-01

Last updated by the study team

2019-01-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Resectable stage I or II non-small-cell lung cancer
• Prior tissue biopsy (not cytology) available for research analysis
• Adequate hepatic and renal function

You may not qualify if…

• Prior chemotherapy or radiotherapy

Where it is running

• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.